Synonyms: NVP-QAW039 | QAW039
Compound class:
Synthetic organic
Comment: Fevipiprant is an orally available, selective antagonist of the prostanoid DP2 receptor (CRTh2) with anti-inflammatory action [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, Holzauer B, Bourne M, Mistry V, Pavord ID et al.. (2016)
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. The Lancet,. |
2. Sykes D, Bradley M, Riddy D, Willard L, Powell-Herlaar E, Sandham D, Watson S, Bauer C, Dubois G, Charlton S. (2014)
QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy. Eur Respir J, 44 (Supl 58): 4074. |
3. Sykes DA, Bradley ME, Riddy DM, Willard E, Reilly J, Miah A, Bauer C, Watson SJ, Sandham DA, Dubois G et al.. (2016)
Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. Mol Pharmacol, 89 (5): 593-605. [PMID:26916831] |